Groups

Groups
E-mail Print PDF

2013

Zoete V, Irving M, Ferber M, Cuendet M, Michielin O.
Structure-based, rational design of T cell receptors.
Frontiers in Immunology, 2013, ;4:268


Ding J, Loizides-Mangold U, Rando G, Zoete V, Michielin O, Reddy JK, Wahli W, Riezman H, Thorens B.
The peroxisomal enzyme L-PBE is required to prevent the dietary toxicity of medium chain fatty acids.
Cell Reports, 2013, 5(1):248-58..


Fagerberg T, Zoete V, Viatte S, Baumgaertner P, Alves PM, Romero P, Speiser DE, Michielin O.
Prediction of cross-recognition of peptide-HLA A2 by Melan-A-specific CTLs using three-dimensional quantitative structure-activity relationships
PLOS One, 2013, 8(7):e65590.


Wirth M, Volkamer A, Zoete V, Rippmann F, Michielin O, Rarey M, Sauer WH.
Protein pocket and ligand shape comparison and its application in virtual screening.
J Comput Aided Mol Des. 2013, 27(6):511-24.


Gfeller D, Michielin O, Zoete V.
SwissSidechain: a molecular and structural database of non-natural sidechains.
Nucleic Acids Res. 2013, 41(Database issue), D327-32.


Wirth M, Zoete V, Michielin O, Sauer W.
SwissBioisostere: A database of molecular replacements for ligand design.
Nucleic Acids Res. 2013, 41(Database issue), D1137-43.


Chen S, Gfeller D, Buth SA, Michielin O, Leiman PG, Heinis C.
Improving binding affinity and stability of Peptide ligands by substituting glycines with d-amino acids.
Chembiochem. 2013, 14, 1316-22.


Lapouge K, Perozzo R, Iwaszkiewicz J, Bertelli C, Zoete V, Michielin O, Scapozza L, Haas D.
RNA pentaloop structures as effective targets of regulators belonging to the RsmA/CsrA protein family.
RNA Biol. 2013, 10.


Gautschi O, Peters S, Zoete V, Aebersold-Keller F, Strobel K, Schwizer B, Hirschmann A, Michielin O, Diebold J.
Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib.
Lung Cancer. 2013, 82(2):365-7


Romano E, Pradervand S, Paillusson A, Weber J, Harshman K, Muehlethaler K, Speiser DE, Peters S, Rimoldi D, Michielin O.
Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression.
Clin Cancer Res. 2013, in press.


Demierre N, Zoete V, Michielin O, Stauffer E, Zimmermann DR, Betticher DC, Peters S.
A dramatic lung cancer course in a patient with a rare EGFR germline mutation exon 21 V843I: Is EGFR TKI resistance predictable?
Lung Cancer. 2013, 80, 81.


Hebeisen M, Baitsch L, Presotto D, Baumgaertner P, Romero P, Michielin O, Speiser DE, Rufer N.
SHP-1 phosphatase activity counteracts increased T cell receptor affinity.
J Clin Invest. 2013, 123, 1044


Peters S, Michielin O, Zimmermann S.
Dramatic Response Induced by Vemurafenib in a BRAF V600E-Mutated Lung Adenocarcinoma.
J Clin Oncol. 2013, 31, e341-4.


Tzika E, Moura B, Romano E, Michielin O.
New therapeutic weapons in stage IV melanoma.
Rev Med Suisse. 2013, 9, 1095


 

google analytics